Bitauto (BITA) is a heavily shorted, low float stock but there is far more to the bull case than a simple short squeeze. As with my long report on RH in the $80s, this report will attract vocal critics. But by the time BITA hits $100 I expect these critics will have long since gone quiet or found more suitable employment. My view that “BITA rises to $240” is not overly optimistic. In fact, it may prove to be too conservative. Read this report first and then simply decide for yourself if BITA could comfortably exceed $17 billion in market cap in the near future. To me, the answer is a very obvious “yes”.

Short interest in BITA has quietly risen to 11.4 million shares. But because the float numbers are not pulling into Bloomberg, most hedge funds are unaware that this now amounts to 80.5% of the tradable float. BITA recently announced a $150 million share buyback which could now reduce the float to well below 11 million shares. The short interest would suddenly exceed 100% of float. BITA has $1.4 billion of cash sitting on its balance sheet to execute a mere $150 million buyback. The buyback was stated to be within the next eight (8) months.

BITA has deep backing from the biggest tech giants in China, including Tencent, Baidu and JD.com. Their familiar descriptors “The Facebook of China”, “The Google of China and “The Amazon of China” are well worn clichés but they are both accurate and highly relevant to BITA. Their ownership and involvement in both BITA and its largest subsidiary Yixin (HK 2858) is far larger and far more involved than the the market realizes. More than 80% of BITA’s tradable float is now gone and they already own roughly half of the Yixin subsidiary. The tech investors acted as a group, purchasing together via a large special purpose vehicle (“SPV”). They are insiders and their shares cannot be easily sold.

BITA’s founder and chairman William Bin Li also happens to be chairman and founder of electric vehicle maker NIO Motors. NIO is slated to come public on the NYSE within months in a $2 billon IPO which would value NIO at $15 billion. By 2020, NIO has stated that it will be selling electric cars in the US in direct competition with Tesla. More recently, Mr. Li was also appointed as chairman of Dida Chuxing AKA “The Uber of China”. Mr Li is currently owns over 10% of the outstanding shares of BITA. Mr. Li is very visibly employing the same tactics and technology approaches used by Apple and FB to conquer all market share in each of his multiple businesses.

With RH, it was “capital structure engineering” that took the stock from $20 in 2017 to $160 in recent weeks. RH was an “8 bagger” from its lows despite its visibly weak fundamentals. The upside with BITA is vastly greater than what we saw with RH, for two reasons. First, the capital structure engineering is far more aggressive with BITA than it ever was with RH. This includes the same sequenced tactics seen at RH: leverage, float reduction, equity/option grants and a share buyback, all coupled with an announced expansion plan.   Second, in contrast to RH’s weak fundamentals, the business prospects and cash generation for BITA are extremely strong. This can be clearly seen by comparing BITA to its competitor Autohome. BITA is now rapidly surpassing Autohome in revenues and growth. Yet Autohome is valued at over $12 billion. The only reason for BITA’s bottom line weakness is that it continues to spend aggressively to secure even more growth. This expensive land grab tactic is exactly what Facebook was doing at the time of its IPO in 2012, and its shares were similarly pummeled down to $17. FB currently trades at around $200.

The auto market in China continues to be one of the largest, fasting growing and most profitable consumer segments in the world. This is why BITA continues to grow revenues at over 50% per year for the past five years, even while keeping gross margins steady at 60-80%. The partnerships with the Chinese tech giants goes both ways. Not only are they eager to secure a piece of BITA’s fast growing penetration into this market, but they are also actively sharing their own mass targeted data with BITA to fuel BITA’s growth even further.

This report is the opinion of the author. It is not a recommendation for anyone anywhere to do anything at any time. Do your own research, form your own opinions. The author is not an investment advisor. The author may conduct transactions on various securities mentioned in this report (or competitors, comparable companies, other securities etc.) within 72 hours or at any time thereafter. The author is long BITA.

Much of the information in this report appears to have been entirely missed by the market. Only 5-10% of Revlon’s shares are in the public float. Only a single analyst covers the stock with only very perfunctory coverage. Revlon’s latest 10Q (May 2018) contains a subtle seven-word change from what was disclosed in the 10K in March. This disclosure now signals that Revlon is gearing up to conduct “asset transfers”, stripping bondholders of collateral so that Revlon can raise between $500 million and $1 billion to ramp up its turnaround program. Such a move is punishing to bondholders but will be sharply rewarding to shareholders because it demonstrates that billionaire Perelman is now entering the final stages of taking Revlon private.

J Crew had made use of a similar “trap door” feature last year to strip bondholders of collateral by shifting IP assets into unrestricted subsidiaries. But Revlon’s ability to move assets to the benefit of shareholders is far, far greater. According to Debtwire: “the trap door mechanics in Revlon are a bit different from J.Crew’s. Revlon’s trap door is more like a black hole.”

Perelman is unequivocally betting on a successful turnaround at Revlon. But he is also using the turnaround plan to acquire his new shares near multi year lows. In 2017, Perelman increased his stake in Revlon to 84.65%, paying up to $23.50. But many of his shares were acquired near multi year lows simply because his turnaround plan front-end-loads the expenses, pressuring the share price.

Right after the about-face on disclosure regarding asset transfers, Revlon immediately appointed Perelman’s daughter (Debra Perelman) as CEO.

Perelman already owns 84.65% of Revlon. In September 2017 he agreed to a standstill at the request of Mittleman Investment, the second largest shareholder. But it was later realized the standstill to which Perelman agreed does not preclude him from making a tender offer in the interim.

Perelman has repeatedly engaged in the same tactics to acquire past companies at bargain prices following very short-term quarterly weakness in financial results which were the predictable result of a planned restructuring. Because Perelman already owns 84.65% of Revlon, the price he pays for the remaining 15.35% stub will not have a meaningful effect on his overall average price. So he can certainly pay a significant premium. Mittleman claims that current fair value should be from $50 to $100. But actually, market comparables would put the price target closer to the lower end of $40-50 at present. In reality, Perelman will attempt to acquire the remaining 15.35% stub as cheaply as possible. He may be able to acquire the final shares at $32-36.

However, due to Revlon’s very low public float and high short interest, the share price could easily overshoot on any positive update. Short interest is over 2 million shares even though the tradable free float is just 5.2m shares (a 40% effective short interest).

Summary In May, RH quietly awarded its CEO a massive nine figure incentive package to achieve a $150 share price by any means. Two days later RH announced a $700m buyback. In 2017, RH already bought back half of all outstanding shares at prices below $50. Stock then doubled. Further financial engineering can easily attain…

Read More

Summary Quite suddenly industry insiders, analysts and media are recasting beleaguered “car rental” plays into lucrative “fleet management” plays, CRUCIAL to the futures of Uber/Lyft. Icahn owns 35% of HTZ and is major Lyft investor. Icahn paying huge premiums to acquire additional targets across rental, ride share, service and parts.  “Vehicles As A Service”. Short…

Read More

Summary Dillard’s appears set up for “infinity squeeze” like VW in 2008, which sent stock up 5x. Einhorn was short VW in 2008, but is now largest outside holder of DDS. Bloomberg shows short interest at 69.9% of float. But it’s worse. Index funds can’t sell. Einhorn won’t. Short interest now over 100% of effective…

Read More

Summary ARA’s JV partners are suddenly exercising their put options nearly as fast as they vest, requiring ARA to buy out their equity stakes. The reasons are becoming clear. Post Q1 news: insurers now rejecting charitable assist on BOTH ACA AND non-ACA plans. Fraud lawsuit against ARA spurred federal investigations into “charities”, now from three…

Read More

Summary On Tuesday, Cemtrex fell 13% on huge volume. On the preceding trading day, Cemtrex’s banker Source Capital quietly had its SEC and FINRA registrations terminated following multiple violations. Over $1 million has been paid to notorious stock promoters sending CETX soaring from below $2. Heavy undisclosed selling by CETX insiders during paid promotion. DOCUMENTS:…

Read More

Summary Heavily promoted by multiple paid promoters (including undisclosed). Stock has spiked to an all-time high. Company is out of cash and is delinquent in its filings. Management with close connections to past frauds. Expect a very near-term financing to drop the stock by at least 30-40%. This article is the opinion of the author….

Read More

Summary The fallout from stock promotions can far outweigh the prospects for a promising drug. Responses (and denials) from management are best viewed with a large grain of salt. There are often significant and far reaching consequences that are often unexpected. Back in March, I wrote a detailed article about a stock promotion campaign being conducted by…

Read More

Summary Investors and analysts have overestimated the market size for SBC-102 by at least 3-9x. Most sufferers of CESD can be treated by proper diet and common statins (i.e. Lipitor) without the need for a $300,000 drug. Management has now sold 95% of its stock, reducing combined holdings to less than 1% of outstanding –…

Read More

Note: At least 13 recent articles covering CytRx have been removed from circulation at Seeking Alpha, the Wall Street Cheat Sheet, Motley Fool and Forbes. Many were removed in just the past two days. A list of these removed articles is shown at the bottom of this article. The author has preserved PDF copies of…

Read More

Investment Thesis     ServiceNow insiders have now sold over $400 million of stock even after its IPO, disregarding bullish calls from research firms (who happen to also be its bankers).   On February 1st – the first day of the February lockup expiration – the CEO and the company founder began selling large amounts…

Read More

  Pacira Pharmaceuticals (PCRX) is an emerging specialty pharma company which in 2012 launched an opiate alternative (“Exparel”) for post surgical pain management. The product is currently approved for use in certain post surgical pain applications including removal of hemorrhoids and bunions. Since the product launch in April 2012, the shares have tripled, enjoying a boost…

Read More

Last week I published an article noting several sell signals which were emerging at Pacira Pharmaceuticals (PCRX), which was closing in on a triple since 2012. In just the past few weeks the shares have risen by more than 50%, to $30.00 from $20.00. Following my article, it was disclosed that MPM Asset Management, which employs both…

Read More